OBJECTIVES: To review European Medicine Agency approvals in oncology for
2006-2012 to determine commonly used primary endpoints and endpoints based on patient reported outcomes (PROs). METHODS: The initial identification of oncology approvals was conducted in PROLabels (2006 PROLabels ( -2012 . This was supplemented with a review of European Assessment Reports, Summary of Product Characteristics, Procedural Steps, Summary of the European Public Assessment Report and Scientific Discussion documents. RESULTS: There were 8 approvals in neoplasms, 3 in anemia, 4 in pain, 1 in nausea and vomiting, 1 in paroxysmal hemoglobinuria. Primary endpoints for approval of oncology drugs included progression free survival (n=5), endpoints based on pain intensity (n=3), overall survival (n=2), hemoglobin stabilization/blood transfusion requirement (n=1), no emesis/no use of rescue medications (n=1), lesion clearance (n=1). PRO measure used included the BPI-SF, MPQ, FACIT-F, FACIT-An, FACT-L, EORTC-QLQ-C30, Pain NRS, nausea VAS, TSQM, Trial Outcomes Index and an unreported measure. The type of PRO endpoints in the approved labeling included: Pain (n=7), HRQOL (n=6), fatigue (n=3), emetic episodes/use of rescue medications (n=1), treatment satisfaction (n=1). CONCLUSIONS: Manufacturers frequently supplement primary endpoints with supplemental PRO data. European approvals include labeling information that is often not permitted by the FDA such as improved HRQOL. 
PCN119 IMPACT OF CULTURE ON THE QUALITY OF LIFE OF MEXICAN-AMERICAN FAMILY CAREGIVERS OF PATIENTS WITH ADVANCED CANCER

OBJECTIVES:
Although Hispanics are the fastest growing ethnic group and cancer the second leading cause of death among Hispanics in the U.S., few studies have documented the impact of cancer diagnosis on the quality of life and caregiving experiences of Hispanic family caregivers. The aim of this study was to explore the influence of culture on the caregiving experiences and perceptions of QOL among Mexican-American (MA) family caregivers of adults with advanced cancer. METHODS: This qualitative descriptive study was conducted in the ambulatory care setting of an NCI-Comprehensive cancer care center in the United States. Twenty MA family caregivers of patients with advanced cancer participated in qualitative interviews. Thematic analysis of the interviews and the conceptual model of Quality of Life Well-being developed by Ferrell, Wisdom, and Wenzel (1989) were used to characterize the caregiving experience and the effects of caregiving on QOL of MA cancer family caregivers. RESULTS: In general, the caregiving experience and the meaning of QOL centered on spiritual or religious beliefs and practices, concern for providing the best home care, inclusion of extended family support, and the desire to fulfill cultural role and responsibility expectations. Overall, MA caregivers emphasized that their caregiving experience had more positive than negative outcomes. The caregiver's overall QOL was primarily affected by the patient's advanced disease, the consequences of the cancer treatment and its related side effects, and the patient's emotional/psychological needs. Secondarily, the caregiver's overall perception of quality of life was affected by their physical, social, emotional and spiritual needs. CONCLUSIONS: These findings provide insight into the cultural dimension inherent in the caregiving experience and perceptions of QOL of MA cancer family caregivers. It is imperative to recognize the influence of culture in developing culturally relevant interventions specifically designed to reduce the burden of cancer and improve overall caregiver QOL.
PCN120 PATIENT REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A SYSTEMATIC REVIEW
Aggarwal S, Segal J, Messenger M Novel Health Strategies, Bethesda, MD, USA OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for collecting and generating evidence for new medical products to show improvements in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer (CRPC) is a chronic disease with high importance for patient HRQoL. The objective of this study was to review, analyze, and understand trends in the PRO instruments used in patients with CRPC. METHODS: A systematic literature search for CRPC randomized controlled trials (RCTs) with PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interventions, year, PRO instrument, and results for PROs. Analysis was conducted to identify trends in commonly used PRO instruments and categorize results as positive, neutral or negative. RESULTS: Ten RCTs with a total of 5797 patients were identified. In these studies there were 13 different PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used in 1,091 patients). Six studies reported positive results with improvement in quality of life symptoms (QoL) versus comparator treatments. Fours studies reported results with deterioration in (QOL). Three studies reported improvement in pain scores. CONCLUSIONS: Patients with CRPC have relatively longer survival and hence QoL is an important consideration for these patients. PRO instruments such as FACT-P and EQC-30 have been commonly used to generate evidence to show which therapies improve patient QoL. 
CANCER -Health Care Use & Policy Studies
PCN121 GAPS IN US AND EU PAYER POLICIES LIMIT THEAPEUTIC OPTIONS IN PAIN CONDITIONS
OBJECTIVES:
Despite a shift towards consideration of pain as a focus of treatment rather than a symptom to be managed, the introduction of new products for pain has been detrimentally affected by reimbursement frameworks that are unlikely to support decisions that favour patient access. This situation exists despite public support for effective pain management, particularly within the palliative care setting. This study aims to identify the mechanisms that limit the available therapeutic options in pain management and to suggest potential alternative approaches to be considered. METHODS: The study involved interviews with 30 interviewees in the US, France, Germany and the UK, including national level HTA influencers, medical directors, influencers on hospital formularies and product use, palliative medicine consultants, anaesthesiologists and oncologists. Interviews focused on the challenges of securing a favourable reimbursement status and a commercially viable price in a pain indication, as well as the difference between treatment guidelines and clinical practice. The success (or not) of market access for 4 selected pain products was also assessed based upon a set of criteria set out in the poster. The organisational structures for delivery of pain services were also considered. RESULTS: New pain products struggle to secure uptake in both the US and EU. Countries adopting a model that attaches the achievable price level with the level of additional clinical benefit demonstrated (France, Germany) are reluctant to consider favourable assessment versus established cheap products. The absence of life extension and common existence of pain in late stage disease means countries adopting a cost-effectiveness model (UK) are methodologically unsuited to evaluation of such products. US payers are likely to place restrictive prior authorisation requirements on products while cheap options exist. CONCLUSIONS: Patient access to new pain therapies is significantly limited by reimbursement policy in the US and EU, including in instances where the product has a recognised clinical benefit. 
PCN122 PREVALENCE, DIAGNOSIS & TREATMENT PROTOCOLS FOR BREAST CANCER IN SOUTHERN PUNJAB
OBJECTIVES:
To explore the prevalence, diagnosis & treatment protocol of breast cancer in patients treated at Bahawalpur institute of nuclear medicine and oncology (BINO). METHODS: A retrospective study was carried out on the data from the treatment records of patients (n=300 
To evaluate the prevalence and patterns of CAM use among cancer patients in Malaysia. In addition, the study focuses on the perceived effectiveness of CAM over conventional therapies, information seeking behaviour and CAM disclosure to health care providers. METHODS: The study was designed as a questionnaire based, cross sectional analysis. A prevalence based sample of 393 cancer patients attending the oncology clinics at Penang General Hospital was hereby selected for the study. Adult patients (18 years old), having diagnosed with cancer (any type), able to read or understand Malay (national language of Malaysia) or English language were recruited between August to November 2011. RESULTS: Overall, 393 questionnaires were completed and included in the analysis, showing that 46.1% of cancer patients had used CAM, with most (57.6%) believing that CAM therapies assisted the body's natural forces to heal. CAM usage was significantly associated with gender (P=0.021), level of education (P=0.001), employment status (P=0.02) and monthly income (P<0.001). Among the frequently used CAM were biologically-based therapies including nutritional supplements (used by 75.5% of the participants). Friends and family members were the most common source of CAM information (for 75.5% of the participants). Only 13% reported side effects from using CAM. CAM use disclosure to the doctors was 43%; however, doctors had specifically asked about CAM use in 33.4% of the cases. The most common reason given for nondisclosure was 'it is not important for the doctors to know about CAM use (34.2%). CONCLUSIONS: Cancer management and treatment requires compliance to effective therapies at early stages. Health care providers should engage cancer patients in an open non-judgmental dialogue to ascertain better understanding of cancer and its treatment options. 
PCN124 INDIVIDUAL RISK PROFILING FOR BREAST CANCER RECURRENCE: TOWARDS TAILORED FOLLOW-UP SCHEMES
OBJECTIVES:
Current international guidelines for breast cancer follow-up are not specific to individual risk of local regional recurrences. Instead, for personalised follow-up it is required to have more precise estimates of local regional recurrence probability as a function of time. The objective of this study is to identify prognostic factors, and to quantify individualized and time dependent local regional recurrence risk rates. METHODS: Prognostic factors for local regional recurrence of breast cancer were identified due to a three-step funnel approach, including: scoping literature review, expert consultation and stepwise multivariate regression analysis. Quantification of the prognostic value of each risk factor was performed with a regression model based on a five-year dataset of women diagnosed with breast cancer in the Netherlands in 2005 or 2006 (n=17762). Six-month interval risk probabilities were derived from regression estimates by calculating coefficients of the prognostic factors. RESULTS: Eight prognostic factors were identified, including: age, tumour size, multifocality, gradation, adjuvant chemo-, adjuvant radiation-, hormonal therapy and triple negative status. Expected inter-patient variability was elucidated by average, and high risk example patient types with local regional, non-uniform distributed, recurrence risks of 5.2% and 12% over a five-year period. CONCLUSIONS: It is concluded that local regional recurrence risks are not distributed uniformly, and time depended, over the five-year follow-up period. The calculated prognostic value of the factors enables quantification of risks for local regional recurrences on six-month time intervals for the individual patient. Implicating improved allocation of hospital capacities and resources, local regional recurrence risk profiling is a first step towards tailored follow-up in breast cancer care. OBJECTIVES: Appropriate use of medical imaging tests is a growing area of policy discussion. Quantitative methods can characterize benefits and risks of medical imaging tests and distinguish necessary from unnecessary utilization. Our objective was to assess the extent of quantitative benefit-risk analyses (BRA) published in medical imaging testing. METHODS: Using PubMed and the Cochrane Library, a computerized search was performed to identify studies published between January, 1979 and January, 2013. The search was limited to include only studies that quantified benefits and risks/harms of ionizing radiation imaging in screening or diagnostics. RESULTS: Seventy-eight studies called for the need to weigh benefits and risks associated with medical imaging tests but only seven studies quantified at least one benefit and one risk/harm. Of these, two studies reported BRA of mammography. Three studies addressed positron emission tomography (PET): two studies assessed BRA of full body PET in cancer screening and one study assessed BRA of PET in lung cancer diagnosis. The remaining two studies reported BRA of computed tomography colonography. Of the four studies published in English, benefits were reported in terms of life extension, and harms were reported as radiation-related cancer risk or loss of life-years. Studies used micro-simulation modeling, epidemiological or survey methods. CONCLUSIONS: This review illustrates that a gap exists between the number of studies referring to the need for assessing the benefitrisk balance in medical imaging and the number of studies measuring that balance. Challenges such as translating imaging information into impacts on patient outcomes, multiple applications of imaging tests, difficulty in measuring harms from ionizing radiation and additional procedures spurred from false positive results hinder the necessary movement toward using quantitative methods. Meeting the goals of patient-centered outcomes and understanding areas of appropriate use, overutilization and underutilization requires further development of a framework for quantitative BRA of medical imaging tests. 
PCN125 QUANTIFICATION OF BENEFITS AND RISKS IN MEDICAL IMAGING TESTING: A LITERATURE REVIEW
PCN126 WHICH IS MORE VALUABLE, LONGER SURVIVAL OR BETTER QUALITY OF LIFE? ISRAELI ONCOLOGISTS' AND FAMILY PHYSICIANS' ATTITUDES TOWARD THE RELATIVE VALUE OF NEW CANCER AND GONGESTIVE HEART FAILURE INTERVENTIONS
OBJECTIVES:
Willingness to pay (WTP) for new health technologies may vary between interventions that prolong patients' life-expectancy and interventions that only improve patients' quality of life (QoL), and among different types of disease. We determined how Israeli oncologists and family physicians value lifeprolongation vs. QoL-enhancing outcomes attributable to cancer and congestive heart failure (CHF) interventions. METHODS: We presented physicians with two scenarios involving a hypothetical patient with metastatic cancer expected to survive 12-months with current treatment. In a life-prolongation scenario, we suggested that a new treatment increases survival at an incremental cost of $50,000 over the standard of care. Participants were asked what minimum improvement in median months of survival the new therapy would need to provide for them to recommend it over standard of care. In the QoL-enhancing scenario, we asked the maximum WTP for an intervention that leads to the same survival as the standard treatment, but increases patient's QoL from 50 to 75 (on a 0-100 scale). We replicated these scenarios substituting a patient with CHF NYHA Class IV instead of metastatic cancer. We derived the incremental costeffectiveness ratio (ICER) per QALY gained threshold implied by each response. RESULTS: In the life-prolongation scenario the median cost-effectiveness thresholds implied by oncologists were $150,000/QALY and $100,000/QALY for cancer and CHF respectively. Median cost-effectiveness thresholds implied by family physicians were $50,000/QALY regardless the disease type. WTP for the QoL-enhancing scenarios was $60,000/QALY and did not differ by physicians' specialty or disease type. CONCLUSIONS: Our findings suggest that family physicians value life-prolonging and QoL-enhancing interventions roughly equally, while oncologists value interventions that extend survival more highly than those that only improve QoL. These findings may have important implications for coverage and reimbursement decisions of new technologies.
PCN127 CANCER DRUG PRICING TRENDS IN THE UNITED STATES AND THE UNITED KINGDOM (2011-2013)
